HEIDELBERG, Germany--(BUSINESS WIRE)--Hummingbird Diagnostics GmbH, a leader in reading blood-based small RNAs for early disease detection and characterization, today announced the initiation of its clinical study evaluating the diagnostic performance of miLungDx, a blood-based small RNA panel engineered to detect non-small cell lung cancer (NSCLC)..

德国海德堡--（商业新闻短讯）--蜂鸟诊断有限公司（Hummingbird Diagnostics GmbH）是阅读基于血液的小RNA用于早期疾病检测和表征的领导者，今天宣布开始其临床研究，评估miLungDx的诊断性能，miLungDx是一种基于血液的小RNA面板，旨在检测非小细胞肺癌（NSCLC）。。

The primary endpoint of the prospective, longitudinal, observational study (NCT05987189) is to detect the absence or presence of lung cancer, as determined by all follow-up imaging and pathological data obtained throughout the duration of the study. Based in the United States, the study will include 2,000 patients with the expected patient enrollment to be completed within 12 months after study initiation..

前瞻性纵向观察性研究（NCT05987189）的主要终点是检测肺癌的存在与否，这是由整个研究期间获得的所有随访影像学和病理学数据确定的。该研究以美国为基地，将包括2000名患者，预计患者登记将在研究开始后12个月内完成。。

“The initiation of patient recruitment for this clinical study marks an exciting milestone for the team at Hummingbird Diagnostics and underscores our mission to improve human health through the development of novel small RNA blood tests,” remarked Bruno Steinkraus, PhD, Chief Scientific Advisor of Hummingbird Diagnostics.

蜂鸟诊断公司首席科学顾问Bruno Steinkraus博士表示：“这项临床研究开始招募患者，标志着蜂鸟诊断公司团队取得了一个令人兴奋的里程碑，并强调了我们通过开发新型小RNA血液检测来改善人类健康的使命。”。

“We believe miLungDx has the best performance reported from a blood test for early-stage lung cancer to date. We look forward to the continued development of this RNA panel.”.

“我们相信miLungDx具有迄今为止早期肺癌血液检测报告的最佳表现。我们期待着这个RNA小组的持续发展。”。

Hummingbird Diagnostics has reported best in class performance for early detection of lung cancer published in the Journal of Thoracic Oncology and presented at ASCO 2023.

蜂鸟诊断公司（Hummingbird Diagnostics）在《胸部肿瘤学杂志》（Journal of Thoratic Oncology）上发表了关于肺癌早期检测的最佳报告，并在ASCO 2023上发表。

About Hummingbird Diagnostics GmbH

关于Hummingbird Diagnostics GmbH

Hummingbird extracts deep insights into disease through the integrated analysis of both tumor and immune system derived small RNA biomarkers from whole blood.

蜂鸟通过对全血中肿瘤和免疫系统衍生的小RNA生物标志物的综合分析，深入了解疾病。

This dual interrogation of signal from disease and the host response to disease enables the highly sensitive, robust, and AI powered mirCator platform that is poised to revolutionize how we diagnose, treat, and manage cancer and other diseases.

这种对来自疾病的信号和宿主对疾病的反应的双重询问使得高度敏感，强大且由AI驱动的mirCator平台能够彻底改变我们诊断，治疗和管理癌症和其他疾病的方式。

To learn more, visit: https://www.hummingbird-diagnostics.com

To learn more, visit:https://www.hummingbird-diagnostics.com